ReviewNature reviews. Cardiology2017
Epidemiology and treatment of pulmonary arterial hypertension.
Review in Nature reviews. Cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 231 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
231 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- Screening for Pulmonary Hypertension in Connective Tissue Diseases: Literature Review and Multidisciplinary Consensus Statement.Anatolian journal of cardiology · 2025Pooled it
- Impact of BMPR2 mutation on the severity of pulmonary arterial hypertension: a systematic review and meta-analysis.Respiratory research · 2025Pooled it
- Searching for Old and New Small-Molecule Protein Kinase Inhibitors as Effective Treatments in Pulmonary Hypertension-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Survival, morbidity, and quality of life in pulmonary arterial hypertension patients: a systematic review of outcomes reported by population-based observational studies.Respiratory research · 2024Pooled it
- Pregnancy conditions and outcomes of Chinese women with mild, moderate and severe pulmonary arterial hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Pooled it
- New progress in diagnosis and treatment of pulmonary arterial hypertension.Journal of cardiothoracic surgery · 2022Pooled it
- Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.JACC. Cardiovascular imaging · 2021Pooled it
- BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?European respiratory review : an official journal of the European Respiratory Society · 2020Pooled it
- Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis.Clinical drug investigation · 2019Pooled it
- Phase 1 Study of MK-5475, an Inhaled Soluble Guanylate Cyclase Stimulator, in Participants with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2024Trial
- Time course of endothelial dysfunction markers and mortality in COVID-19 patients: A pilot study.Clinical and translational medicine · 2021Trial
- Bioequivalence and Tolerability of Ambrisentan: A Pharmacokinetic Study in Mexican Healthy Male Subjects.European journal of drug metabolism and pharmacokinetics · 2020Trial
- Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.BMC cardiovascular disorders · 2020Trial
- Real-World Characteristics, Treatment Patterns, and Clinical Outcomes of Patients Initiated on Macitentan/Tadalafil Single-Tablet Combination Therapy in the United States.Advances in therapy · 2026Article
- Real-World Experience of Midodrine in Hospital Setting in Pulmonary Arterial Hypertension.CHEST pulmonary · 2026Article
- A large animal model of heritable pulmonary arterial hypertension using BMPR2 gene-edited sheep.JCI insight · 2026Article
- Design, Synthesis, and Evaluation of Diphenylpyrazinyl Amino Cycloalkoxy Acetic Acids as IP Receptor Agonists.ACS medicinal chemistry letters · 2026Article
- Ventricular arrhythmogenesis in pulmonary hypertension: From right ventricular remodeling to clinical implications.Physiological reports · 2026Review
- Socioeconomic Burden of Pulmonary Arterial Hypertension in Patients and Caregivers: A Canadian Cross-Sectional Study.CJC open · 2026Article
- Variation inCirculation research · 2026Article
171 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past 2 decades, major changes have occurred in the epidemiological and treatment landscape of pulmonary arterial hypertension (PAH). Previously regarded as a disease of the young and middle-aged, contemporary registries from the Western world have demonstrated an increase in the age of patients with PAH, many of whom are elderly with multiple comorbidities. Another important observation is the improvement in survival of patients with PAH in the modern treatment era compared with historical cohorts, before the availability of advanced therapy. The management of PAH has also become more complex, and numerous drugs are now approved that target the endothelin 1, nitric oxide, and prostacyclin pathways. Combining drugs from different classes is now considered the standard of care and has been demonstrated to improve outcomes. Furthermore, the current treatment paradigm is the early use of combination therapy, often at the time of diagnosis, particularly in patients with severe disease. This Review provides a comprehensive update on the epidemiology and pharmacotherapy of PAH.
Indexed as
Identifiers
28593996What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.